BlackRock
FDMT icon

BlackRock’s 4D Molecular Therapeutics FDMT Stock Holding History

BlackRock’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.5M Buy
4,546,059
+400,756
+10% +$3.9M ﹤0.01% 2551
2026
Q1 		$38.6M Buy
4,145,303
+80,427
+2% +$700K ﹤0.01% 2686
2025
Q4 		$30.5M Buy
4,064,876
+195,746
+5% +$1.99M ﹤0.01% 2830
2025
Q3 		$33.6M Sell
3,869,130
-141,625
-4% -$846K ﹤0.01% 2764
2025
Q2 		$14.9M Sell
4,010,755
-536,397
-12% -$1.89M ﹤0.01% 3189
2025
Q1 		$14.7M Sell
4,547,152
-374,169
-8% -$1.76M ﹤0.01% 3107
2024
Q4 		$27.4M Buy
4,921,321
+52,532
+1% +$412K ﹤0.01% 2841
2024
Q3 		$52.6M Sell
4,868,789
-28,108
-0.6% -$466K ﹤0.01% 2442
2024
Q2 		$103M Buy
4,896,897
+612,349
+14% +$15.4M ﹤0.01% 2013
2024
Q1 		$137M Buy
4,284,548
+819,961
+24% +$20.9M ﹤0.01% 1881
2023
Q4 		$70.2M Buy
3,464,587
+340,911
+11% +$4.49M ﹤0.01% 2290
2023
Q3 		$39.8M Buy
3,123,676
+209,246
+7% +$3.5M ﹤0.01% 2532
2023
Q2 		$52.7M Buy
2,914,430
+363,695
+14% +$6.7M ﹤0.01% 2447
2023
Q1 		$43.8M Buy
2,550,735
+42,103
+2% +$819K ﹤0.01% 2533
2022
Q4 		$55.7M Buy
2,508,632
+278,233
+12% +$4.3M ﹤0.01% 2389
2022
Q3 		$17.9M Buy
2,230,399
+47,641
+2% +$431K ﹤0.01% 3097
2022
Q2 		$15.2M Buy
2,182,758
+52,532
+2% +$511K ﹤0.01% 3249
2022
Q1 		$32.2M Buy
2,130,226
+42,544
+2% +$668K ﹤0.01% 2862
2021
Q4 		$45.8M Buy
2,087,682
+649,319
+45% +$15.9M ﹤0.01% 2711
2021
Q3 		$38.8M Buy
1,438,363
+706,953
+97% +$20.2M ﹤0.01% 2831
2021
Q2 		$17.6M Buy
731,410
+184,006
+34% +$5.63M ﹤0.01% 3380
2021
Q1 		$23.7M Buy
547,404
+541,476
+9,134% +$24M ﹤0.01% 3088
2020
Q4 		$246K Buy
+5,928
New +$245K ﹤0.01% 4445

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock's FDMT Position: Q2 2026 in Review

BlackRock increased its 4D Molecular Therapeutics (FDMT) stake by 9.7% in Q2 2026, buying an estimated $3.9M and bringing the position to 4,546,059 shares worth $60.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2551.

BlackRock first reported a position in FDMT in Q4 2020 and has held it in 23 quarters since. The position peaked at $137M in Q1 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • BlackRock held 4,546,059 shares of 4D Molecular Therapeutics worth $60.5M as of Q2 2026.
  • BlackRock bought 400,756 4D Molecular Therapeutics shares in Q2 2026, an estimated $3.9M.
  • 4D Molecular Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2551 holding.
  • BlackRock first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • BlackRock's 4D Molecular Therapeutics position peaked at $137M in Q1 2024.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.